Welcome to our dedicated page for Telefonica news (Ticker: VIV), a resource for investors and traders seeking the latest updates and insights on Telefonica stock.
Telefónica (VIV), a global leader in telecommunications operating brands like Vivo, Movistar, and O2, provides essential connectivity and digital services across 21 countries. This page aggregates official press releases and verified news about corporate developments, financial performance, and strategic initiatives.
Investors and stakeholders will find timely updates on quarterly earnings, infrastructure investments, and technological innovations, including 5G deployment and cloud solutions. The curated collection features announcements about market expansions, partnerships, and sustainability efforts shaping the company's position in the telecom sector.
Content is organized chronologically for tracking trends over time, with clear sourcing for transparency. Regular visitors gain insights into operational milestones through primary documents and expert analyses. Bookmark this page to monitor how Telefónica navigates evolving demands in digital connectivity and enterprise solutions.
Avivagen Inc. (TSXV:VIV) has approved the issuance of 577,500 stock options to its officers, directors, consultants, and employees. These options will vest over an eight-quarter period and are exercisable within five years at a strike price of $0.56. This issuance forms part of the total remuneration package for these individuals. Additionally, the grants are subject to approval from the TSX Venture Exchange. Avivagen focuses on products for livestock, companion animals, and human health, leveraging its OxC-beta™ technology to promote immune function and improve health economically.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has announced it will seek approval from the TSX Venture Exchange to extend the expiration date of warrants for 2,774,992 common shares at $0.90 per share, originally set to expire on March 31, 2021, to June 1, 2021. This extension is subject to approval by the exchange and will not alter any other terms of the warrants. Avivagen focuses on developing products that enhance immune function in livestock, companion animals, and humans, utilizing its OxC-beta™ technology as a non-antibiotic alternative in livestock feeds.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has announced the publication of a study in Poultry Science demonstrating the benefits of its OxC-betaTM Livestock product for broiler poultry. The research highlights significant improvements in growth performance and feed efficiency in birds supplemented with OxC-beta compared to control groups. Conducted in Canada and Scotland, the trials support OxC-beta as a non-antibiotic alternative for enhancing poultry health and performance. CEO Kym Anthony emphasizes the publication's validation of OxC-beta's commercial benefits, appealing to customers aiming to reduce antibiotic use.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) announces its Q1 2021 financial results, reporting revenues of $261,987 and a comprehensive loss of $(1,266,300). Major milestones include securing a recurring order of 6 tonnes with Transformadora Agricola in Mexico and fulfilling orders in the Philippines, Taiwan, and Thailand. Subsequent achievements include a $7.5 million oversubscribed financing and expansion into Central and South America with Meyenberg International. The company emphasizes a bright outlook for 2021 with increased order volumes anticipated.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) announces its partnership with Meyenberg International Group to expand OxC-beta™ Livestock into Central and South America. Meyenberg, crucial to Avivagen's success in Mexico, will seek registrations in Costa Rica, Colombia, Peru, Uruguay, and Argentina. The five countries had a combined livestock feed consumption of approximately 40 million tonnes in 2020. OxC-beta™ Livestock offers a non-antibiotic solution to promote animal health and is already available in several countries, including the U.S. and Canada.
Telefônica Brasil (NYSE: VIV) announced its 4Q20 and full-year 2020 financial results, revealing a dip in net operating revenues, down 1.6% year-on-year for 4Q and 2.6% for the year. Mobile revenues increased by 1.6%, while fixed revenues fell by 7.7% in the fourth quarter. EBITDA stood at R$4,877 million, with a margin of 43.6%. The company achieved a net income of R$1,293 million for the quarter but a decline of 4.6% for the year, totaling R$4,771 million. Notably, free cash flow rose 12.6% to a record R$9,610 million, and a dividend payout of 113.6% was proposed for shareholders.
Mimi's Rock Corp. (TSXV:MIMI) and Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) have launched Dr. Tobias Beta Blend, a dietary supplement aimed at enhancing immune support and promoting skin and eye health. Available exclusively on Amazon and DrTobias.com, the product leverages Avivagen’s proprietary OxC-beta™ technology. Retailing at USD $29.97, this collaboration is expected to meet strong consumer demand, particularly in light of heightened awareness of immune health due to COVID-19.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has secured a six-tonne order of OxC-beta™ Livestock from Transformadora Agricola de Alimentos S.A. de C.V in Mexico, starting April 2021 with monthly shipments of 500 kilograms. This is Avivagen's second significant order in Mexico within months, following a ten-tonne order in September 2020. CEO Kym Anthony expressed excitement over this new partnership and noted growing demand for their products in Mexico, where trials are ongoing with other prospective customers.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) reported its fiscal 2020 results, showcasing significant growth across several metrics. Revenues reached $1,177,857, up from $977,451 in 2019, while the comprehensive loss narrowed to $(4,751,287) compared to $(4,836,420) in the previous year. The company secured regulatory approvals in critical markets, including Malaysia, Brazil, and support from COFCO Biotech for the Chinese market. Significant orders for OxC-beta™ Livestock were recorded in various countries, highlighting a strong market position. Total assets were reported at $2,176,142, against total liabilities of $6,943,752.
Telefônica Brasil announced its 3Q20 results on Oct. 27, showcasing record fiber net adds and a recovery in prepaid services. Net Operating Revenues were R$10,792 million (-2.3% y-o-y), while Net Income rose by 25.5% to R$1,212 million. The company achieved a 40.0% EBITDA margin on R$4,322 million EBITDA. The fiber broadband customer base increased by 34.2%, accounting for nearly half of broadband accesses. Free Cash Flow reached R$3,540 million, up 34.5% y-o-y. The launch of Vivo Money, a digital lending platform, marked the expansion into financial services.
